Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Clinical trial NCT03878199 · TERMINATED

Trial details

NCT number: NCT03878199
Sponsor: Ohio State University Comprehensive Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasm Polycythemia Vera Secondary Acute Myeloid Leukemia

Start date: 2019-02-20
Primary completion: 2025-02-27
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.